{"id":53454,"date":"2025-05-06T17:33:46","date_gmt":"2025-05-06T21:33:46","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?p=53454"},"modified":"2025-05-12T14:26:39","modified_gmt":"2025-05-12T18:26:39","slug":"session-highlight-ecd-treatment-options-current-and-on-the-horizon","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/pt\/session-highlight-ecd-treatment-options-current-and-on-the-horizon\/","title":{"rendered":"Destaque da sess\u00e3o: Op\u00e7\u00f5es de tratamento para a ECD \u2013 Atuais e futuras"},"content":{"rendered":"

Speaker: Julien Haroche, MD, PhD<\/strong>
\nTime: 9:35 AM \u2013 9:55 AM
\nDate: May 26, 2025 Patient & Family Gathering\u00a0<\/strong><\/p>\n

In the world of Erdheim-Chester Disease (ECD), few names are more widely respected than Dr. Julien Haroche. For more than two decades, Dr. Haroche has led groundbreaking research in histiocytosis, particularly ECD. At this year\u2019s Patient and Family Gathering in Barcelona, his session titled \u201cECD Treatment Options: Current and on the Horizon\u201d<\/strong> promises to be a powerful overview of how far treatment has come\u2014and what lies ahead.<\/p>\n

A Global Leader in ECD Treatment Innovation<\/h3>\n

Dr. Haroche is based at H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re in Paris, France, where he and his team have treated more than 250 patients , making their program one of the most experienced ECD centers in the world. His clinical research has played a significant role in defining treatment protocols that are now used globally, particularly those involving\u00a0patients with BRAF or other MAPK pathway mutations.<\/p>\n

In 2012, his team was the first to use these therapies in adults with histiocytosis, a development that changed the trajectory for many patients. Before that, options were limited and outcomes unpredictable. Now, while ECD remains complex, treatment is more tailored, precise, and often more effective.<\/p>\n

What You\u2019ll Learn in This Session<\/h3>\n

This talk will serve as a clear, non-technical guide for patients and families seeking to understand how treatment decisions are made. Dr. Haroche will address several critical questions, including:<\/p>\n

    \n
  • What treatments are available today, and how do doctors determine which one is appropriate?<\/li>\n
  • What role do genetic mutations\u2014especially BRAFV600E<\/strong>\u2014play in determining treatment?<\/li>\n
  • How are targeted therapies different from traditional approaches, and what can patients expect in terms of administration, duration, and monitoring?<\/li>\n<\/ul>\n

    He\u2019ll also cover considerations around treatment intensity<\/strong>, including when it\u2019s possible to take a \u201cwatchful waiting\u201d approach and when more aggressive intervention is necessary.<\/p>\n

    Why This Session Matters<\/h3>\n

    Understanding treatment options can be one of the most empowering aspects of living with ECD. For many patients, the road to diagnosis is long and filled with uncertainty. Gaining clarity around what can be done\u2014and why\u2014often brings a sense of hope and control.<\/p>\n

    If you or your loved one is considering treatment, currently undergoing therapy, or seeking insight into what the future may hold, this is a must-attend session.<\/p>\n

    The ECDGA encourages all attendees to bring questions and engage. While Dr. Haroche and his colleagues cannot offer personal medical advice in this forum, the information shared may help you have more informed conversations with your care team at home.<\/p>","protected":false},"excerpt":{"rendered":"

    Speaker: Julien Haroche, MD, PhD Time: 9:35 AM \u2013 9:55 AM Date: May 26, 2025 Patient & Family Gathering\u00a0 In the world of Erdheim-Chester Disease (ECD), few names are more […]<\/p>\n","protected":false},"author":14,"featured_media":55183,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[51],"tags":[594,375,378,387,380,383,374,384,386,376,385],"class_list":["post-53454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-barcelona","tag-ecdawareness","tag-ecdcommunity","tag-ecdga","tag-ecdsupport","tag-ecdvolunteer","tag-erdheimchesterdisease","tag-hopeforecd","tag-makerarevisible","tag-raredisease","tag-supportraredisease"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/posts\/53454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/comments?post=53454"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/posts\/53454\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/media\/55183"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/media?parent=53454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/categories?post=53454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/tags?post=53454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}